Evidence map›Paper›PMID 34550326›Full record

ArticleCardiovascular research2022

The adult heart requires baseline expression of the transcription factor Hand2 to withstand right ventricular pressure overload.

Raquel F Videira, Anne Marie C Koop, Lara Ottaviani, Ella M Poels, Jordy M M Kocken, Cristobal Dos Remedios, Pedro Mendes-Ferreira, Kees W Van De Kolk, Gideon J Du Marchie Sarvaas, André Lourenço and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Cardiovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Rare TruncatingGenes · 2026
    Article
  2. Article
  3. TRIAGE: an R package for regulatory gene analysis.Briefings in bioinformatics · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Raquel F VideiraDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands.ORCID 0000-0002-7017-2487
Anne Marie C KoopDepartment of Pediatrics, University of Groningen, University Medical Center Groningen, Center for Congenital Heart Diseases, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Lara OttavianiDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands.ORCID 0000-0002-5216-5099
Ella M PoelsDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands.ORCID 0000-0002-1067-2404
Jordy M M KockenDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands.ORCID 0000-0001-7202-4771
Cristobal Dos RemediosDepartment of Anatomy and Histology, University of Sidney, Sidney, NSW 2006 and Molecular Cardiology Group at Victor Chang Cardiac Research institute, Darlinghurst, NSW 2010, Australia.ORCID 0000-0003-1052-7490
Pedro Mendes-FerreiraDepartment of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Alameda professor Hernâni Monteiro, 4200-319 Porto, Portugal.ORCID 0000-0003-3616-6785
Kees W Van De KolkUniversity Medical Center Groningen, The Central Animal Facility, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Gideon J Du Marchie SarvaasDepartment of Pediatrics, University of Groningen, University Medical Center Groningen, Center for Congenital Heart Diseases, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
André LourençoDepartment of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Alameda professor Hernâni Monteiro, 4200-319 Porto, Portugal.
Aida Llucià-ValldeperasDepartment of Pulmonary Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, PHEniX laboratory, Amsterdam Cardiovascular Sciences, De Boelelaan 1108, 1081HZ Amsterdam, The Netherlands.
Dian aS Nascimentoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.ORCID 0000-0001-6402-4245
Leon J De WindtDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands.
Frances S De ManDepartment of Pulmonary Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, PHEniX laboratory, Amsterdam Cardiovascular Sciences, De Boelelaan 1108, 1081HZ Amsterdam, The Netherlands.
Inês Falcão-PiresDepartment of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Alameda professor Hernâni Monteiro, 4200-319 Porto, Portugal.
Rolf M F BergerDepartment of Pediatrics, University of Groningen, University Medical Center Groningen, Center for Congenital Heart Diseases, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Paula A da Costa MartinsDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands.
Universidade do Porto · PTMaastricht University · NLUniversity Medical Center Groningen · NLAmsterdam University Medical Centers · NLVictor Chang Cardiac Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsResearch on the pathophysiology of right ventricular (RV) failure has, in spite of the associated high mortality and morbidity, lagged behind compared to the left ventricle (LV). Previous work from our lab revealed that the embryonic basic helix-loop-helix transcription factor heart and neural crest derivatives expressed-2 (Hand2) is re-expressed in the adult heart and activates a 'foetal gene programme' contributing to pathological cardiac remodelling under conditions of LV pressure overload. As such, ablation of cardiac expression of Hand2 conferred protection to cardiac stress and abrogated the maladaptive effects that were observed upon increased expression levels. In this study, we aimed to understand the contribution of Hand2 to RV remodelling in response to pressure overload induced by pulmonary artery banding (PAB). METHODS AND

resultsIn this study, Hand2F/F and MCM- Hand2F/F mice were treated with tamoxifen (control and knockout, respectively) and subjected to six weeks of RV pressure overload induced by PAB. Echocardiographic- and MRI-derived haemodynamic parameters as well as molecular remodelling were assessed for all experimental groups and compared to sham-operated controls. Six weeks after PAB, levels of Hand2 expression increased in the control-banded animals but, as expected, remained absent in the knockout hearts. Despite the dramatic differences in Hand2 expression, pressure overload resulted in impaired cardiac function independently of the genotype. In fact, Hand2 depletion seems to sensitize the RV to pressure overload as these mice develop more hypertrophy and more severe cardiac dysfunction. Higher expression levels of HAND2 were also observed in RV samples of human hearts from patients with pulmonary hypertension. In turn, the LV of RV pressure-overloaded hearts was also dramatically affected as reflected by changes in shape, decreased LV mass, and impaired cardiac function. RNA-sequencing revealed a distinct set of genes that are dysregulated in the pressure-overloaded RV, compared to the previously described pressure-overloaded LV.

conclusionCardiac-specific depletion of Hand2 is associated with severe cardiac dysfunction in conditions of RV pressure overload. While inhibiting Hand2 expression can prevent cardiac dysfunction in conditions of LV pressure overload, the same does not hold true for conditions of RV pressu re overload. This study highlights the need to better understand the molecular mechanisms driving pathological remodelling of the RV in contrast to the LV, in order to better diagnose and treat patients with RV or LV failure.

Indexed as

Heart FailureVentricular Dysfunction, RightAnimalsBasic Helix-Loop-Helix ProteinsHeart VentriclesHumansMiceRNATamoxifenTranscription FactorsVentricular Function, RightVentricular PressureVentricular RemodelingBasic Helix-Loop-Helix ProteinsRNATamoxifenTranscription FactorsHand2Heart failureRight ventricle remodellingTranscriptional regulation

Identifiers

PMID34550326
PMCPMC9491876
OpenAlexW3199635667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.